B7-H4 expression and its role in interleukin-2/interferon treatment of clear cell renal cell carcinoma

Oncology Letters

Volumn 7, Issue 5, 2014, Pages 1474-1478

  Xu, Yipeng ^a   Zhu, Shaoxing ^a   Song, Mei ^a   Liu, Weihui ^b   Liu, Chengyi ^c   Li, Yongsheng ^b   Wang, Min ^d  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

B7 H4; Clear cell renal cell carcinoma; Cytokines; Tumor immunity

Indexed keywords

ALPHA INTERFERON; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 2; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; UPREGULATION;

EID: 84896304438     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1961     Document Type: Article

References (19)

1. Yang JC, Sherry RM, Steinberg SM, et al: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21: 3127-3132, 2003.
2. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696, 1995.
3. Dangaj D, Lanitis E, Zhao A, et al: Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T cell antitumor responses. Cancer Res 73: 4820-4829, 2013.
4. Tringler B, Zhuo S, Pilkington G, et al: B7-h4 is highly expressed in ductal and 1obular breast cancer. Clin Cancer Res 11: 1842-1848, 2005.
5. Kryczek I, Zou L, Rodriguez P, et al: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203: 871-881, 2006.
6. Choi IH, Zhu G, Sica GL, et al: Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 171: 4650-4654, 2003.
7. Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung cancer 53: 143-151, 2006.
8. Quandt D, Fiedler E, Boettcher D, et al: B7-h4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin Cancer Res 17: 3100-3111, 2011.
9. Krambeck AE, Thompson RH, Dong H, et al: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103: 10391-10396, 2006.
10. Bromwich EJ, McArdle PA, Canna K, et al: The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89: 1906-1908, 2003.
11. Nakano O, Sato M, Naito Y, et al: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132-5136, 2001.
12. Couillard DR and DeVere-White RW: Surgery of renal cell carcinoma. Urol Clin North Am 20: 263-275, 1993.
13. Zang X, Loke P, Kim J, et al: B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 100: 10388-10392, 2003.
14. Prasad DV, Richards S, Mai XM and Dong C: B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18: 863-873, 2003.
15. Sica GL, Choi IH, Zhu G, et al: B7-H4, a molecule of the B7 family member, negatively regulates T cell immunity. Immunity 18: 849-861, 2003.
16. Kryczek I, Wei S, Zhu G, et al: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 67: 8900-8905, 2007.
17. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
18. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
19. Ribas A: Tumor immunotherapy directed at PD-1. N Eng J Med 366: 2517-2519, 2012.